Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.

Qian ZR, Rubinson DA, Nowak JA, Morales-Oyarvide V, Dunne RF, Kozak MM, Welch MW, Brais LK, Da Silva A, Li T, Li W, Masuda A, Yang J, Shi Y, Gu M, Masugi Y, Bui J, Zellers CL, Yuan C, Babic A, Khalaf N, Aguirre A, Ng K, Miksad RA, Bullock AJ, Chang DT, Tseng JF, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar M, Wollison B, Laing A, Hahn WC, Meyerson M, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Wolpin BM.

JAMA Oncol. 2018 Mar 8;4(3):e173420. doi: 10.1001/jamaoncol.2017.3420. Epub 2018 Mar 8.

2.

Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.

Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G, Kim S, Assie G, Morozova O, Akbani R, Shih J, Hoadley KA, Choueiri TK, Waldmann J, Mete O, Robertson AG, Wu HT, Raphael BJ, Shao L, Meyerson M, Demeure MJ, Beuschlein F, Gill AJ, Sidhu SB, Almeida MQ, Fragoso MCBV, Cope LM, Kebebew E, Habra MA, Whitsett TG, Bussey KJ, Rainey WE, Asa SL, Bertherat J, Fassnacht M, Wheeler DA; Cancer Genome Atlas Research Network, Hammer GD, Giordano TJ, Verhaak RGW.

Cancer Cell. 2016 May 9;29(5):723-736. doi: 10.1016/j.ccell.2016.04.002. Erratum in: Cancer Cell. 2016 Aug 8;30(2):363.

3.

Comment on "The consensus coding sequences of human breast and colorectal cancers".

Getz G, Höfling H, Mesirov JP, Golub TR, Meyerson M, Tibshirani R, Lander ES.

Science. 2007 Sep 14;317(5844):1500.

4.

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.

Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O'Neill K, Khan H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M, Mellinghoff IK.

PLoS Med. 2006 Dec;3(12):e485.

5.

Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.

Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, Golub T, Meyerson M, Tenen DG, Shapiro GI, Halmos B.

Cancer Res. 2006 Dec 1;66(23):11389-98.

6.

Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts.

Hayes DN, Monti S, Parmigiani G, Gilks CB, Naoki K, Bhattacharjee A, Socinski MA, Perou C, Meyerson M.

J Clin Oncol. 2006 Nov 1;24(31):5079-90. Review.

PMID:
17075127
7.

Phosphorylation of the menin tumor suppressor protein on serine 543 and serine 583.

MacConaill LE, Hughes CM, Rozenblatt-Rosen O, Nannepaga S, Meyerson M.

Mol Cancer Res. 2006 Oct;4(10):793-801.

8.

TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.

Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA.

Cancer Res. 2006 Sep 1;66(17):8337-41.

9.

Epidermal growth factor receptor mutation testing in the care of lung cancer patients.

Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4403s-4408s. Review.

10.

Genomic approaches to lung cancer.

Thomas RK, Weir B, Meyerson M.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4384s-4391s. Review.

11.

Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.

Lynch TJ, Adjei AA, Bunn PA Jr, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jänne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4365s-4371s. No abstract available.

12.

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA.

Clin Cancer Res. 2006 Jul 1;12(13):3908-14.

13.

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

Shimamura T, Ji H, Minami Y, Thomas RK, Lowell AM, Shah K, Greulich H, Glatt KA, Meyerson M, Shapiro GI, Wong KK.

Cancer Res. 2006 Jul 1;66(13):6487-91.

14.

Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing.

Thomas RK, Nickerson E, Simons JF, Jänne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, Gutmann EJ, Dragnev KH, DeBiasi R, Chen TH, Glatt KA, Greulich H, Desany B, Lubeski CK, Brockman W, Alvarez P, Hutchison SK, Leamon JH, Ronan MT, Turenchalk GS, Egholm M, Sellers WR, Rothberg JM, Meyerson M.

Nat Med. 2006 Jul;12(7):852-5. Epub 2006 Jun 25. Erratum in: Nat Med. 2006 Oct;12(10):1220.

PMID:
16799556
15.

C/EBP alpha mutations in lung cancer.

Costa DB, Dayaram T, D'Alo F, Wouters BJ, Tenen DG, Meyerson M, Tsao MS, Halmos B.

Lung Cancer. 2006 Aug;53(2):253-4. Epub 2006 Jun 12. No abstract available.

PMID:
16765476
16.

Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays.

Beroukhim R, Lin M, Park Y, Hao K, Zhao X, Garraway LA, Fox EA, Hochberg EP, Mellinghoff IK, Hofer MD, Descazeaud A, Rubin MA, Meyerson M, Wong WH, Sellers WR, Li C.

PLoS Comput Biol. 2006 May;2(5):e41. Epub 2006 May 12.

17.

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.

Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung BL, McNamara K, Xia H, Glatt KA, Thomas RK, Sasaki H, Horner JW, Eck M, Mitchell A, Sun Y, Al-Hashem R, Bronson RT, Rabindran SK, Discafani CM, Maher E, Shapiro GI, Meyerson M, Wong KK.

Proc Natl Acad Sci U S A. 2006 May 16;103(20):7817-22. Epub 2006 May 3.

19.

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.

Jänne PA, Borras AM, Kuang Y, Rogers AM, Joshi VA, Liyanage H, Lindeman N, Lee JC, Halmos B, Maher EA, Distel RJ, Meyerson M, Johnson BE.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):751-8.

Supplemental Content

Loading ...
Support Center